UPDATE: LifeTech Capital Downgrades Echo Therapeutics Following Capital Raise
UPDATE: LifeTech Capital Reiterates Strong Speculative Buy Rating, Lowers PT on Echo Therapeutics on Clinical Progress
UPDATE: LifeTech Capital Downgrades Echo Therapeutics Following Capital Raise
UPDATE: LifeTech Capital Reiterates Strong Speculative Buy Rating, Lowers PT on Echo Therapeutics on Clinical Progress
LifeTech Capital Maintains Strong Speculative Buy on Navidea After Alseres Agreement
UPDATE: LifeTech Capital Downgrades NovaBay to Neutal, Drops PT to $1.25
LifeTech Capital Maintains Strong Speculative Buy on Navidea After Alseres Agreement
UPDATE: LifeTech Capital Downgrades NovaBay to Neutal, Drops PT to $1.25
LifeTech Capital Downgrades NovaBay Pharmaceuticals to Neutral
LifeTech Capital Maintains Strong Buy Rating and $4.75 PT on Oculus Innovative Sciences
LifeTech Capital Recent News
LifeTech Capital Maintains Bionovo Strong Speculative Buy, Lowers PT
LifeTech Capital Reiterates Buy and PT of $2.50 on NovaBay
LifeTech Capital Raises StemCells PT to $8, Maintains Strong Speculative Buy
LifeTech Capital Maintains Strong Buy on Oculus Innovative Sciences
LifeTech Capital Maintains Echo Therapeutics Strong Speculative Buy, $6 PT
LifeTech Capital Comments on Neoprobe, Maintains Strong Speculative Buy
LifeTech Capital Downgrades Marina Biotech To Neutral, $0.30 PT
LifeTech Capital Updates Echo Therapeutics With Strong Speculative Buy, $6 PT
LifeTech Capital Positive On Marina Biotech (MRNA)
LifeTech Capital On NBY Catheter Research
LifeTech Capital Maintains Strong Buy Rating, $4 PT On NBS
LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)
LifeTech Capital Maintains Strong Speculative Buy on StemCells (STEM)
LifeTech Capital Maintains Bionovo Strong Speculative Buy, $7.50 PT (BNVI)
LifeTech Capital Raises Echo Therapeutics PT To $6 (ECTE)
LifeTech Capital Initiates Marina Biotech at Strong Speculative Buy (MRNA)